Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISIBLE 2: Vedolizumab SC Maintenance in Crohn's Disease
NCT02611817Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2016
- Primary completion
- May 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 30
01
Overview
A Phase 3 trial of vedolizumab in Crohn's disease, sponsored by Takeda. Started Jan 2016; status: completed.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02611817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02611817.